Research programme: arthritis therapy - Galapagos/ZoBio/Pyxis Discovery/Leiden University

Drug Profile

Research programme: arthritis therapy - Galapagos/ZoBio/Pyxis Discovery/Leiden University

Alternative Names: Arthritis therapy research programme - Galapagos, ZoBio, Pyxis Discovery, Leiden University

Latest Information Update: 24 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV; Leiden University; Pyxis Discovery; ZoBio
  • Developer Galapagos NV; Pyxis Discovery; ZoBio
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 24 May 2010 Discontinued - Preclinical for Rheumatic disorders in Netherlands (unspecified route)
  • 12 Aug 2005 Preclinical trials in Rheumatic disorders in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top